Ternary Therapeutics

Ternary Therapeutics is an early-stage, privately-held biotech pioneering a computational platform for the rational design of molecular glues. The company combines advanced machine learning and molecular dynamics simulations to identify and optimize compounds that induce novel protein-protein interactions, primarily for targeted protein degradation and activation. Backed by European venture capital, TernaryTx is advancing a pre-clinical pipeline focused on inflammatory and fibrotic diseases while leveraging the expertise of a team with a strong track record in AI-driven drug discovery.

Proprietary computational platform integrating machine learning and molecular dynamics for the rational design of molecular glues. Includes modules for ternary complex hotspot identification (Leopard), effector protein prioritization (Puffin), binding site discovery (Gecko), and glue-specific virtual screening (Octopus).

TernaryTx operates in the highly competitive fields of AI-driven drug discovery and targeted protein degradation. Key competitors include public molecular glue specialists (e.g., Monte Rosa Therapeutics), large pharma with internal TPD efforts (e.g., Novartis, BMS, Roche), and other AI-native drug discovery companies applying similar tools to different modalities. Differentiation relies on the specific efficacy of its proprietary platform for glue discovery.